Acutus medical update: berger montague investigates securities fraud allegations against acutus medical, inc. (nasdaq: afib); lead plaintiff deadline is april 18, 2022

Philadelphia, march 4, 2022 /prnewswire/ --  berger montague is investigating securities fraud allegations on behalf of investors who purchased the securities of acutus medical, inc. ("acutus" or the "company") (nasdaq: afib) between may 13, 2021 and november 11, 2021 (the "class period"). if you purchased acutus securities during the class period, would like to discuss berger montague's investigation, or have questions concerning your rights or interests, please contact attorneys andrew abramowitz at aabramowitz@bm.net or (215) 875-3015, or michael dell'angelo at mdellangelo@bm.net or (215) 875-3080 or visit: https://investigations.bergermontague.com/acutus-medical-inc-/  whistleblowers: anyone with non-public information regarding acutus is encouraged to confidentially assist berger montague's investigation or take advantage of the sec whistleblower program.
AFIB Ratings Summary
AFIB Quant Ranking